Velden et al. reported that parenchymal enhancement in the contralateral breast of patients with invasive unilateral breast cancer is significantly associated with long-term outcome, particularly in patients with ER-positive, HER2-negative breast cancer [10]. Here, ERBB2 is linked to breast cancer.